Publication date: Sep 22, 2023
This study analyzes the impact of COVID-19 variants on cost-effectiveness across age groups, considering vaccination efforts and nonpharmaceutical interventions in Republic of Korea. We aim to assess the costs needed to reduce COVID-19 cases and deaths using age-structured model. The proposed age-structured model analyzes COVID-19 transmission dynamics, evaluates vaccination effectiveness, and assesses the impact of the Delta and Omicron variants. The model is fitted using data from the Republic of Korea between February 2021 and November 2022. The cost-effectiveness of interventions, medical costs, and the cost of death for different age groups are evaluated through analysis. The impact of different variants on cases and deaths is also analyzed, with the Omicron variant increasing transmission rates and decreasing case-fatality rates compared to the Delta variant. The cost of interventions and deaths is higher for older age groups during both outbreaks, with the Omicron outbreak resulting in a higher overall cost due to increased medical costs and interventions. This analysis shows that the daily cost per person for both the Delta and Omicron variants falls within a similar range of approximately $10-$35. This highlights the importance of conducting cost-effect analyses when evaluating the impact of COVID-19 variants.
Open Access PDF
| Concepts | Keywords |
|---|---|
| Daily | Age |
| Fatality | Analyzes |
| Korea | Cost |
| November | Costs |
| Vaccination | Covid |
| Deaths | |
| Delta | |
| Effectiveness | |
| Groups | |
| Interventions | |
| Model | |
| Omicron | |
| Structured | |
| Vaccination | |
| Variants |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | VO | effectiveness |
| disease | MESH | COVID-19 |
| disease | VO | vaccination |
| disease | MESH | death |
| disease | MESH | Long Covid |
| drug | DRUGBANK | Coenzyme M |
| disease | IDO | country |
| disease | MESH | infections |
| disease | VO | effective |
| disease | VO | PreM |
| disease | VO | time |
| pathway | REACTOME | Reproduction |
| disease | VO | age |
| disease | VO | vaccine |
| disease | IDO | intervention |
| disease | VO | vaccine effectiveness |
| disease | VO | vaccine efficacy |
| disease | VO | Canada |
| disease | VO | vaccinated |
| disease | VO | dose |
| disease | VO | population |
| disease | VO | vaccination coverage |
| disease | VO | dead |
| disease | IDO | infection |
| disease | IDO | susceptibility |
| disease | IDO | infectivity |
| disease | VO | unvaccinated |
| disease | IDO | susceptible population |
| disease | VO | USA |
| disease | VO | organization |
| drug | DRUGBANK | Ilex paraguariensis leaf |
| drug | DRUGBANK | Iodine |
| disease | MESH | vector borne diseases |
| disease | MESH | yellow fever |
| disease | MESH | premature mortalities |
| drug | DRUGBANK | Trestolone |